Treatment of a Case of Severe Insulin Resistance Due to a PIK3R1 Mutation With a Sodium-Glucose Cotransporter-2 Inhibitor

Journal of Diabetes Investigation - Australia
doi 10.1111/jdi.12825
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
2019English

Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
2018English

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin

Pharmaceutics
Pharmaceutical Science
2020English

Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model

Yonago Acta Medica
Medicine
2019English

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2019English

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Corrigendum to a Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2019English

Increased Grip Strength With Sodium-Glucose Cotransporter 2

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2016English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy